MX2019002066A - Regimen de dosificacion para el tratamiento de tumores solidos. - Google Patents
Regimen de dosificacion para el tratamiento de tumores solidos.Info
- Publication number
- MX2019002066A MX2019002066A MX2019002066A MX2019002066A MX2019002066A MX 2019002066 A MX2019002066 A MX 2019002066A MX 2019002066 A MX2019002066 A MX 2019002066A MX 2019002066 A MX2019002066 A MX 2019002066A MX 2019002066 A MX2019002066 A MX 2019002066A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- solid tumors
- dosage regimen
- oxo
- administering
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporciona un régimen de dosificación, el cual comprende administrar la 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hidroxi-etil) -6-oxo-7H-pirido-[2,3-d][3]-benzazepin-7-il]-amino]-1-metil-2-oxo -etil]-butanamida o una sal farmacéuticamente aceptable o hidrato de la misma, para el tratamiento de un cáncer de tumor sólido en una dosis de carga especificada durante un período de dosificación definido, seguida por una dosis de mantenimiento y, de una forma opcional, administrar un corticosteroide durante la administración de la dosis de carga.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381911P | 2016-08-31 | 2016-08-31 | |
| PCT/US2017/048308 WO2018044662A1 (en) | 2016-08-31 | 2017-08-24 | Dosage regimen for treatment of solid tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002066A true MX2019002066A (es) | 2019-06-03 |
Family
ID=59772787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002066A MX2019002066A (es) | 2016-08-31 | 2017-08-24 | Regimen de dosificacion para el tratamiento de tumores solidos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190209581A1 (es) |
| EP (1) | EP3506905B1 (es) |
| JP (2) | JP2019526632A (es) |
| KR (1) | KR102512899B1 (es) |
| CN (2) | CN116473978A (es) |
| AU (1) | AU2017321011B2 (es) |
| BR (1) | BR112019002461A2 (es) |
| CA (1) | CA3035616A1 (es) |
| IL (2) | IL305136A (es) |
| MA (1) | MA46086A (es) |
| MX (1) | MX2019002066A (es) |
| SG (2) | SG10202107832UA (es) |
| WO (1) | WO2018044662A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| KR102418765B1 (ko) | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 |
| CA3020918A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
| WO2017200969A1 (en) | 2016-05-20 | 2017-11-23 | Eli Lilly And Company | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
| CA3039405A1 (en) | 2016-10-12 | 2018-04-19 | Eli Lilly And Company | Targeted treatment of mature t-cell lymphoma |
| ES2949364T3 (es) | 2017-02-17 | 2023-09-28 | Fred Hutchinson Cancer Center | Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US46206A (en) | 1865-02-07 | Improved vessel for holding petroleum | ||
| US8633179B2 (en) * | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
| SI3354276T1 (sl) * | 2007-11-13 | 2020-09-30 | Meritage Pharma, Inc. | Sestavki za zdravljenje gastrointestinalnega vnetja |
| AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| EP3166627A1 (en) * | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
| TWI609687B (zh) * | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
-
2017
- 2017-08-24 MA MA046086A patent/MA46086A/fr unknown
- 2017-08-24 SG SG10202107832UA patent/SG10202107832UA/en unknown
- 2017-08-24 CN CN202310314953.4A patent/CN116473978A/zh active Pending
- 2017-08-24 WO PCT/US2017/048308 patent/WO2018044662A1/en unknown
- 2017-08-24 IL IL305136A patent/IL305136A/en unknown
- 2017-08-24 AU AU2017321011A patent/AU2017321011B2/en active Active
- 2017-08-24 IL IL264924A patent/IL264924B2/en unknown
- 2017-08-24 SG SG11201901325UA patent/SG11201901325UA/en unknown
- 2017-08-24 EP EP17761723.0A patent/EP3506905B1/en active Active
- 2017-08-24 CA CA3035616A patent/CA3035616A1/en active Pending
- 2017-08-24 JP JP2019531873A patent/JP2019526632A/ja active Pending
- 2017-08-24 KR KR1020197005847A patent/KR102512899B1/ko active IP Right Grant
- 2017-08-24 US US16/328,267 patent/US20190209581A1/en active Pending
- 2017-08-24 MX MX2019002066A patent/MX2019002066A/es unknown
- 2017-08-24 CN CN201780052146.2A patent/CN109562114A/zh active Pending
- 2017-08-24 BR BR112019002461A patent/BR112019002461A2/pt unknown
-
2022
- 2022-12-27 JP JP2022209634A patent/JP2023052108A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018044662A1 (en) | 2018-03-08 |
| US20190209581A1 (en) | 2019-07-11 |
| CN116473978A (zh) | 2023-07-25 |
| BR112019002461A2 (pt) | 2019-05-14 |
| EP3506905B1 (en) | 2024-03-20 |
| AU2017321011A1 (en) | 2019-02-21 |
| KR20190042591A (ko) | 2019-04-24 |
| IL264924B2 (en) | 2024-01-01 |
| SG10202107832UA (en) | 2021-09-29 |
| JP2019526632A (ja) | 2019-09-19 |
| IL264924A (es) | 2019-04-30 |
| AU2017321011B2 (en) | 2023-08-03 |
| EP3506905A1 (en) | 2019-07-10 |
| CN109562114A (zh) | 2019-04-02 |
| SG11201901325UA (en) | 2019-03-28 |
| JP2023052108A (ja) | 2023-04-11 |
| KR102512899B1 (ko) | 2023-03-23 |
| MA46086A (fr) | 2019-07-10 |
| CA3035616A1 (en) | 2018-03-08 |
| IL264924B1 (en) | 2023-09-01 |
| IL305136A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019002066A (es) | Regimen de dosificacion para el tratamiento de tumores solidos. | |
| MX2022013410A (es) | Metodos de tratamiento. | |
| RU2018101314A (ru) | Комбинированные способы лечения антагонистами pd-l1 | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| JP2019506403A5 (es) | ||
| MX2023001468A (es) | Tratamiento de cancer de prostata. | |
| WO2007084670A3 (en) | Specific therapy using integrin ligands for treating cancer | |
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| MX2019012884A (es) | Terapia de combinacion. | |
| MX2009007597A (es) | Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer. | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| JP2017537927A5 (es) | ||
| MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| EP4252847A3 (en) | Regimens and methods of treating multiple sclerosis using ofatumumab | |
| JP2018511642A5 (es) | ||
| MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| UA115250C2 (uk) | Фармацевтичні комбінації | |
| MX2019004602A (es) | Agentes anti-proliferativos para tratar pah. | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| WO2010057596A3 (en) | New therapy and medicament using integrin ligands for treating cancer | |
| MX2022006626A (es) | Terapia para tratamiento de cancer. |